Zhitong Finance App News, Shanghai Yizhong (688091.SH) announced that the self-developed innovative drug YXC-001 (trifunctional antibody fusion protein) from Shanghai Youxichuang Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, has recently completed the first administration of the first dose group in the phase I clinical trial.

In response to the pain point where it is difficult to balance the efficacy and toxicity of existing single-target drugs, the company has forwardly laid out the world's leading next-generation anti-tumor class 1 drug YXC-001 based on an exclusive multifunctional antibody development platform. As a first-in-class trifunctional antibody fusion protein with a unique structure, YXC-001 can be expected to break through the existing limitations of advanced solid tumor treatment by accurately integrating PD-1 antibodies (pabolizil), anti-VEGF antibodies (bevacizumab), and optimized IL-2 (adipelucin) with optimized low toxicity.

Preclinical pharmacodynamics studies showed that in mouse lung cancer models, YXC-001 was significantly superior to the control drug PD-1 monoclonal antibody (Keytruda) and the PD-1/VEGF bispecific antibody drug at the same dose, and showed an excellent dose-efficacy relationship.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.